Clinical pharmacokinetics of adefovir in human immunodeficiency virus type 1-infected patients
暂无分享,去创建一个
A. Collier | J. Toole | H. Jaffe | A C Collier | K. Cundy | K C Cundy | P Barditch-Crovo | R E Walker | D Ebeling | J Toole | H S Jaffe | R. E. Walker | D. Ebeling | Jay Toole | P. Barditch‐Crovo | Ann C. Collier | H. S. Jaffe | Robert E. Walker | Ann C. Collier | Darlene Ebeling | Howard S. Jaffe
[1] M. H. Gault,et al. Prediction of creatinine clearance from serum creatinine. , 1975, Nephron.
[2] E. Clercq. Broad-spectrum anti-DNA virus and anti-retrovirus activity of phosphonylmethoxyalkylpurines and -pyrimidines , 1991 .
[3] E. De Clercq,et al. Marked in vivo antiretrovirus activity of 9-(2-phosphonylmethoxyethyl)adenine, a selective anti-human immunodeficiency virus agent. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[4] M. Connelly,et al. Metabolism and in vitro antiretroviral activities of bis(pivaloyloxymethyl) prodrugs of acyclic nucleoside phosphonates , 1993, Antimicrobial Agents and Chemotherapy.
[5] L. Klunk,et al. Determination of 9-[(2-phosphonylmethoxy)ethyl]adenine in rat urine by high-performance liquid chromatography with fluorescence detection. , 1991, Journal of chromatography.
[6] H. Ho,et al. Biochemical Pharmacology of Acyclic Nucleotide Analogues , 1990, Annals of the New York Academy of Sciences.
[7] E. De Clercq,et al. Intracellular metabolism and mechanism of anti-retrovirus action of 9-(2-phosphonylmethoxyethyl)adenine, a potent anti-human immunodeficiency virus compound. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[8] R. Barbhaiya,et al. Quantitation of didanosine in human plasma and urine by high-performance liquid chromatography. , 1990, Journal of chromatography.
[9] E. De Clercq,et al. Phosphonylmethoxyethyl purine derivatives, a new class of anti-human immunodeficiency virus agents , 1988, Antimicrobial Agents and Chemotherapy.
[10] K. Mayer,et al. Pharmacokinetics of stavudine in patients with AIDS or AIDS-related complex. , 1992, The Journal of infectious diseases.
[11] Cockcroft Dw,et al. Prediction of Creatinine Clearance from Serum Creatinine , 1976 .
[12] E. De Clercq,et al. Suppression of feline immunodeficiency virus infection in vivo by 9-(2-phosphonomethoxyethyl)adenine. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[13] E. De Clercq,et al. Pharmacokinetics in mice of the anti-retrovirus agent 9-(2-phosphonylmethoxyethyl)adenine. , 1992, Drug metabolism and disposition: the biological fate of chemicals.
[14] E. De Clercq,et al. Acyclic adenine nucleoside phosphonates in plasma determined by high-performance liquid chromatography with fluorescence detection. , 1992, Clinical chemistry.
[15] J. Shaw,et al. Oral, subcutaneous, and intramuscular bioavailabilities of the antiviral nucleotide analog 9-(2-phosphonylmethoxyethyl) adenine in cynomolgus monkeys , 1994, Antimicrobial Agents and Chemotherapy.
[16] M. Polis,et al. Clinical pharmacokinetics of cidofovir in human immunodeficiency virus-infected patients , 1995, Antimicrobial agents and chemotherapy.
[17] E. De Clercq,et al. 9-(2-Phosphonylmethoxyethyl)adenine (PMEA) effectively inhibits retrovirus replication in vitro and simian immunodeficiency virus infection in rhesus monkeys. , 1991, AIDS.
[18] E. De Clercq. Broad-spectrum anti-DNA virus and anti-retrovirus activity of phosphonylmethoxyalkylpurines and -pyrimidines. , 1991, Biochemical pharmacology.